Acticor Makes Case For First-In-Class Heart Drug Glencozimab
French Biotech Initiates Phase II/III Trials
Executive Summary
As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.